Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Radiotherapy in High-risk HNSCC
NCT05024019Phase 2Unknown
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Aug 2021
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eye and ENT Hospital of Fudan University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05024019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024019.